New kidney cancer treatment

People with advanced kidney cancer are set to benefit from a new treatment after NICE has said lenvatinib should be available on the NHS.

The drug is recommended as an option for people who have previously been treated for advanced real cell carcinoma (RCC).

Lenvatinib works by blocking the signals that a cancer cell needs to grow and divide.

The evidence from a clinical trial suggests that, on average, people live around 10.1 months longer if they have lenvatinib plus everolimus rather than everolimus alone.

A revised offer from the company also means the NICE committee found the treatment cost effective.

This means they will now recommend lenvatinib (plus everolimus) as an option for advanced RCC in adults who have had one previous treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho